Cytokinetics CYTK CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's capex?
- Cytokinetics (CYTK) reported capex of $5.93M in Q1 2026.
- How has Cytokinetics's capex changed year-over-year?
- Cytokinetics's capex increased by 4.7% year-over-year, from $5.66M to $5.93M.
- What is the long-term trend for Cytokinetics's capex?
- Over 4 years (2021 to 2025), Cytokinetics's capex has grown at a -15.6% compound annual growth rate (CAGR), from $48.87M to $24.81M.
- What does capex mean?
- Cash spent on physical assets like equipment and facilities.
- How do you interpret capex?
- Higher spending signals investment in future capacity or infrastructure, while lower spending may indicate a focus on asset-light operations or cost containment.
- How does capex compare across companies?
- Biotech companies typically have lower CapEx compared to manufacturing-heavy industries, focusing primarily on lab equipment and facility leases.